publication date: Oct. 17, 2014

Stand Up To Cancer Canada to Fund Two Dream Teams

Stand Up To Cancer Canada will support two, four-year cancer research dream teams with nearly $20 million USD raised by SU2C Canada collaborators and from the charity’s September telecast. The dream teams will focus their research on translational research in breast cancer and cancer stem cells.

The $22.6 million CAD was raised together with Canadian Breast Cancer Foundation with support from CIBC, Cancer Stem Cell Consortium, Genome Canada, Canadian Institutes of Health Research, and the Ontario Institute for Cancer Research.

The American Association for Cancer Research International – Canada, SU2C Canada’s scientific partner, issued calls for ideas.

Research proposals will be reviewed by the SU2C Canada Scientific Advisory Committee, co-chaired by Nobel Laureate Phillip Sharp, institute professor at the Massachusetts Institute of Technology and David H. Koch Institute for Integrative Cancer Research at MIT; and Alan Bernstein, president and CEO of the Canadian Institute for Advanced Research.

The Stand Up To Cancer Canada-Canadian Breast Cancer Foundation Breast Cancer Dream Team will provide up to $6 million CAD. Ideas are invited for a translational cancer research project that will include new therapeutic interventions for breast cancer that would be expected to reduce progression and improve overall survival.

The Stand Up To Cancer Canada Cancer Stem Cell Dream Team will provide approximately $10.6 million CAD, supporting a pan-Canadian team of researchers, clinicians and nongovernmental organizations focusing on the role of cancer stem cells and stem cell programs on resistance and treatment failure in cancer, with an emphasis on genomics.

Additionally, the two teams may each receive supplementary funds up to $3 million over four years from OICR, to support clinical trial activities in the province of Ontario.

Letters of Intent must be submitted by Dec. 8 using the proposalCENTRAL website. General information on eligibility criteria, the application process, and other details are available at Inquiries may be directed to the AACR International-Canada at 416-797-5366 or

Copyright (c) 2020 The Cancer Letter Inc.